FORM 4 [X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Treco Douglas A
2. Issuer Name and Ticker or Trading Symbol

Ra Pharmaceuticals, Inc. [ RARX ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
President and CEO
(Last)          (First)          (Middle)

C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)

4/2/2020
(Street)

CAMBRIDGE, MA 02140
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 4/2/2020  D  234707 (1)D$48.00 (2)0 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy) $2.87 4/2/2020  D     139371 (2)  (3)12/10/2025 Common Stock 139371 $0 (3)0 D  
Stock Option (Right to Buy) $2.87 4/2/2020  D     241460 (2)  (3)12/10/2025 Common Stock 241460 $0 (3)0 D  
Stock Option (Right to Buy) $5.60 4/2/2020  D     164285 (2)  (3)8/16/2026 Common Stock 164285 $0 (3)0 D  
Stock Option (Right to Buy) $16.64 4/2/2020  D     225000 (2)  (3)2/1/2027 Common Stock 225000 $0 (3)0 D  
Stock Option (Right to Buy) $7.33 4/2/2020  D     125000 (2)  (3)2/1/2028 Common Stock 125000 $0 (3)0 D  
Stock Option (Right to Buy) $21.00 4/2/2020  D     311000 (2)  (3)2/1/2029 Common Stock 311000 $0 (3)0 D  
Restricted Stock Units  (4)4/2/2020  D     20833 (2)  (4) (4)Common Stock 20833 $0 (4)0 D  

Explanation of Responses:
(1) Includes (i) 377 shares of Issuer common stock acquired under the Issuer's Employee Stock Purchase Plan on December 10, 2019 and (ii) 14,620 shares of Issuer common stock acquired upon the vesting and net settlement of restricted stock units on February 1, 2020.
(2) Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the "Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
(3) Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.
(4) Pursuant to the Merger Agreement, at the effective time of the Merger, each restricted stock unit was canceled in exchange for a cash payment equal to $48.00 per share underlying each restricted stock unit.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Treco Douglas A
C/O RA PHARMACEUTICALS, INC.
87 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
X
President and CEO

Signatures
/s/ David C. Lubner, Attorney-in Fact for Douglas A. Treco4/3/2020
**Signature of Reporting PersonDate

Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Ra Pharmaceuticals Charts.
Ra Pharmaceuticals (NASDAQ:RARX)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Ra Pharmaceuticals Charts.